Genome Sequencing of Marburg and Ebola Viruses

Genome Sequencing of Marburg and Ebola Viruses

You are here

Filoviruses, such as Ebola Virus and Marburg virus, are examples of agents that induce hemorrhagic fever (VHF) and can result in high mortality (up to ~90 percent). Both Ebola and Marburg viruses and closely related strains cause severe diseases in humans and nonhuman primates. All the members of Filoviridae are select agents, Risk Group 4 Pathogens (requiring BL4-equvalent containment), and Category A Priority Pathogens. Filoviruses are negative sense RNA viruses in the order Mononegavirales and as the order delineates, the genome is single stranded negative sense RNA that is ~19 Kb in length. The increased frequency of outbreaks of hemorrhagic fever caused by Ebola-like strains in central and western Africa and the potential use of such agents as biological weapons underscore the need to understand pathogenesis of these viruses and to develop effective vaccines and antivirals.

This project generated complete genome consensus sequences for filovirus stocks, and was capable of identifying any contaminating pathogens in the existing stocks--including other filoviruses strains. Additionally, the study allowed novel insight into the role that multiplicity of infection (MOI) plays on the diversity of strains during passage in culture, while simultaneously providing knowledge about the level of nucleotide and amino acid variation within the virus population.

The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.
PloS one. 2017-01-01; 12.6: e0178717.
PMID: 28636653
Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.
Cell reports. 2016-02-23; 14.7: 1632-1640.
PMID: 26876165
Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells.
mBio. 2014-11-04; 5.6: e02011.
PMID: 25370495

This project has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Award Numbers N01-AI30071 and U19AI110819.